TNFSF11 and osteoporosis: Currently, bisphosphonate (e.g., alendronate, risedronate), selective estrogen receptor modulators (SERMs) and RANKL antibody (denosumab) (Maximov et al., 2013; Pazianas and Abrahamsen, 2016; Qiao and Tang, 2018) are representative components inhibiting osteoporosis.